Comments by "ricardo kowalski" (@ricardokowalski1579) on "Unstable endemicity" video.

Anybody with high BMI, high sugar, high blood pressure that wanted others to take medication to protect themselves already had brain damage. So there is that confounding factor
34
@tonstril i mean that some people were already brain damaged before taking the jab or testing positive
6
There is no point talking about data anymore, because all the data is flawed Subjects never investigated or studied, but surely memory holed: - PCR adequacy as diagnostic tool. How many months did an individual test PCR positive after recovery? Confounding PCR positive with no symptoms (ie, exposed to the virus) as a case (ie developed illness) - Treatment guidance was that no treatment was available, every attempt to repurpose or develop care was delayed, or shutdown. - By allowing infected and symptomatic to develop grave symptoms (for lack of early treatment) then intubation/ventilation guaranteed death by sepsis , not virus - No prophylaxis or early treatment was allowed to be tested or developed because it is a condition for emergency authorization usage of the shots - The data of the shots development was never published, and had to be fought for, and is revealing that it was known it failed EUA criteria. - The EUA approval criteria was changed to "stimulate an inmune response" - Data of deaths by age and body mass index was never published and is still hidden - No retrospective study of the models or their suitability The above is just a partial list of "data" sins.
2
RESULTS Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI: 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7th month after the primary infection, but waned to ∼70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and <10% by the 32nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of <10% by the 15th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9- 98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning . Similar results were found in sub-group analyses for those ≥50 years of age. medrxiv 2022.07.06.22277306v1 Duration of immune protection of (......) natural infection against reinfection in Qatar This is still a pre-print, bla bla.
1
@loudigity0 yep
1